BioSpace News Archive

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fourth quarter and full year financial results for the full year 2021.

DURECT Corporation announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022.

Merrimack Pharmaceuticals, Inc. announced its full year 2021 financial results for the period ended December 31, 2021.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results.

Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), announces that Transcenta has presented the safety/tolerability and preliminary anti-tumor activity data in gastric and pancreatic cancers of TST001 China phase I clinical trial as a poster presentation at the 2022 International Gastric Cancer Congress (IGCC).

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 61,000 shares of the Company’s common stock at an exercise price per share of $33.03 which was the closing price on March 8, 2022, and restricted stock units to acquire a total of 30,500 shares of the Company’s common stock.

Glaucoma Research Foundation announced a total of $1.3 million in annual research grants to support 10 investigators at prominent universities across the US.